Shares of Novavax (NVAX) jumped by a staggering 59.22% in 30 days from $131.69 to $209.68 at 20:28 EST on Friday, following the last session’s downward trend. NASDAQ Composite (NVAX) is rising 0.35% to $14,069.42, following the last session’s upward trend.

Novavax’s last close was $204.94, 38.21% under its 52-week high of $331.68.


Today’s last reported volume for Novavax is 2499670 which is 29.78% below its average volume of 3559584.

The company’s growth estimates for the present quarter is a negative 1110% and positive 15% for the next.

Novavax’s Revenue

Year-on-year quarterly revenue growth grew by 3072.2%, now sitting on 475.6M for the twelve trailing months.


Novavax’s last week, last month’s, and last quarter’s current volatility was 4.65%, 2.19%, and 5.09%, respectively.

Novavax’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 4.65% (last week), 4.34% (last month), and 5.09% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Novavax’s stock is considered to be oversold (<=20).

Novavax’s Stock Yearly Top and Bottom Value

Novavax’s stock is valued at $209.68 at 20:28 EST, way under its 52-week high of $331.68 and way above its 52-week low of $43.60.

Novavax’s Moving Average

Novavax’s worth is way above its 50-day moving average of $175.11 and way above its 200-day moving average of $177.04.

Previous days news about Novavax (NVAX)

Novavax to host Maryland governor larry hogan at site of future Novavax vaccines innovation campus and global headquarters. According to Business Insider on Wednesday, 9 June, "About Novavax Novavax, Inc.(Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. ", "These risks and uncertainties include those identified under the heading "Risk Factors" in the Novavax Annual Report on Form 10-K for the year endedDecember 31, 2020, as filed with theSecurities and Exchange Commission(SEC). "

More news about Novavax (NVAX).


Please enter your comment!
Please enter your name here